Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Journal of Thoracic Oncology - Tập 18 - Trang 657-663 - 2023
Jarushka Naidoo1, Scott Antonia2, Yi-Long Wu3, Byoung Chul Cho4, Piruntha Thiyagarajah5, Helen Mann5, Michael Newton6, Corinne Faivre-Finn7
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland
2Duke University School of Medicine, Durham, North Carolina
3Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China
4Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
5Department of Global Medicines Development, AstraZeneca, Cambridge, United Kingdom
6Department of Global Medicines Development, AstraZeneca, Gaithersburg, Maryland
7The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Journal of Thoracic Oncology

Tập 18

657-663

Thông tin tác giả